Lipella Pharmaceuticals (LIPO) News Today $2.40 -0.01 (-0.41%) Closing price 04/17/2025 03:59 PM EasternExtended Trading$2.40 0.00 (0.00%) As of 04/17/2025 04:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Lipella Pharmaceuticals Inc.: Lipella Pharmaceuticals Completes Enrollment in Phase 2a Trial of LP-310 for Oral Lichen PlanusApril 8, 2025 | finanznachrichten.deLipella Pharmaceuticals completes enrollment in LP-310 trialApril 8, 2025 | markets.businessinsider.comLipella enrols all subjects in Phase IIa trial targeting oral lichen planusApril 8, 2025 | finance.yahoo.comLipella Pharmaceuticals Completes Enrollment in Phase 2a Trial of LP-310 for Oral Lichen PlanusApril 8, 2025 | globenewswire.comLipella Pharmaceuticals Co-Founder Michael Chancellor Featured on the Pharmaverse PodcastMarch 31, 2025 | globenewswire.comLipella Pharmaceuticals files to sell 5.62M shares of common stock for holdersMarch 29, 2025 | markets.businessinsider.comSpartan Capital Securities, LLC Announces Key February TransactionsMarch 7, 2025 | globenewswire.comSpartan Capital Securities, LLC Serves as Sole Placement Agent in Lipella Pharmaceuticals Inc.’s $3,788,000 Private PlacementMarch 4, 2025 | finance.yahoo.comSpartan Capital Securities, LLC Serves as Sole Placement Agent in Lipella Pharmaceuticals Inc.'s $3,788,000 Private PlacementMarch 4, 2025 | globenewswire.comBiotech Rips On Topline AnalysisFebruary 11, 2025 | msn.comLipella Pharmaceuticals reports ‘positive’ results from Phase 2a LP-310 trialFebruary 11, 2025 | markets.businessinsider.comLipella Pharmaceuticals Reports Positive Topline Phase 2a Results for LP-310 in the Treatment of Oral Lichen PlanusFebruary 11, 2025 | globenewswire.comThese 5 Health Care Stocks Saw The Sharpest Retail Interest Jump Last WeekFebruary 10, 2025 | msn.comFDA approves Lipella's oral treatment access programFebruary 6, 2025 | msn.comFDA Approves Expanded Access Program For Lipella Pharma's LP-310 In Oral Lichen Planus; Stock UpFebruary 6, 2025 | markets.businessinsider.comLipella Pharmaceuticals Granted FDA Approval for Expanded Access Program for LP-310 in Oral Lichen PlanusFebruary 6, 2025 | globenewswire.comSpartan Capital Securities, LLC Serves as Sole Placement Agent in Lipella Pharmaceuticals Inc.’s $875,500 Private PlacementJanuary 10, 2025 | markets.businessinsider.comSpartan Capital Securities, LLC Serves as Sole Placement Agent in Lipella Pharmaceuticals Inc. ...January 10, 2025 | gurufocus.comSpartan Capital Securities, LLC Serves as Sole Placement Agent in Lipella Pharmaceuticals Inc.'s $875,500 Private PlacementJanuary 10, 2025 | investing.comSpartan Capital Securities, LLC Serves as Sole Placement Agent in Lipella Pharmaceuticals Inc.'s $875,500 Private PlacementJanuary 10, 2025 | globenewswire.comSpartan Capital Securities, LLC Caps Off a Remarkable Year with Key December TransactionsDecember 31, 2024 | globenewswire.comSpartan Capital Securities, LLC Serves as Sole Placement Agent in Lipella Pharmaceuticals Inc.'s $1.72 Million Private PlacementDecember 18, 2024 | globenewswire.comLipella Pharmaceuticals announces publication in CUREUSDecember 4, 2024 | markets.businessinsider.comMaxim Group Keeps Their Buy Rating on Lipella Pharmaceuticals, Inc. (LIPO)November 21, 2024 | markets.businessinsider.comLipella Pharmaceuticals Announces Completion of First Cohort in Phase 2a Trial of LP-310 for Oral Lichen Planus, Advancing to Next Dose GroupNovember 21, 2024 | globenewswire.comLipella Pharmaceuticals Faces Nasdaq Delisting Risk Amid Compliance ChallengesNovember 16, 2024 | markets.businessinsider.comLipella issued patent by USPTO for liposomal drug delivery platformNovember 13, 2024 | markets.businessinsider.comLipella Pharmaceuticals Secures Extended Market Exclusivity with Issuance of U.S. Patent for Liposomal Delivery PlatformNovember 12, 2024 | globenewswire.comLipella Pharmaceuticals Announces 1-for-8 Reverse Stock SplitNovember 1, 2024 | globenewswire.comLipella Pharmaceuticals to Present at 2024 Spartan Capital Investor ConferenceOctober 29, 2024 | globenewswire.comLipella Pharmaceuticals Inc.: Lipella Pharmaceuticals Announces U.S. Patent Allowance for Innovative Liposomal Drug Delivery PlatformOctober 15, 2024 | finanznachrichten.deLipella Pharmaceuticals Announces U.S. Patent Allowance for Innovative Liposomal Drug Delivery PlatformOctober 15, 2024 | globenewswire.comLipella Pharmaceuticals to Present at 2024 Maxim Healthcare Virtual SummitOctober 9, 2024 | globenewswire.comLipella Pharmaceuticals (NASDAQ:LIPO) Stock, Short Interest ReportSeptember 26, 2024 | benzinga.comBuy Rating on Lipella Pharmaceuticals Backed by Promising Phase 2a Results for Oral Lichen Planus TreatmentSeptember 25, 2024 | markets.businessinsider.comPRISM MarketView Features Q&A with Dr. Michael Chancellor: Lipella Pharmaceuticals Advances Innovative Treatments for Hemorrhagic Cystitis During Urology Awareness MonthSeptember 25, 2024 | globenewswire.comLipella Pharmaceuticals Launches Innovative Registry to Advance Oral Lichen Planus ResearchAugust 22, 2024 | globenewswire.comLipella Pharmaceuticals Unveils Advanced Bladder Imaging Technique at ICICJ ConferenceAugust 21, 2024 | globenewswire.comLipella Pharmaceuticals Second Quarter 2024 Earnings: US$0.12 loss per share (vs US$0.27 loss in 2Q 2023)August 18, 2024 | finance.yahoo.comLipella Pharmaceuticals Inc.: Lipella Pharmaceuticals Doses First Two Patients in Phase 2a Oral Lichen Planus Clinical TrialAugust 14, 2024 | finanznachrichten.deBuy Rating Affirmed: Lipella Pharmaceuticals’ Innovative Drug Delivery and Clinical Advancements Propel OptimismAugust 13, 2024 | markets.businessinsider.comLipella doses first two subjects in Phase IIa oral lichen planus treatment trialAugust 12, 2024 | finance.yahoo.comLipella Pharmaceuticals Doses First Two Patients in Phase 2a Oral Lichen Planus Clinical TrialAugust 12, 2024 | globenewswire.comLipella Pharmaceuticals (NASDAQ:LIPO) Stock Quotes, Forecast and News SummaryJuly 31, 2024 | benzinga.comLipella Pharmaceuticals Inc.: Lipella Pharmaceuticals Initiates Phase 2a Trial for LP-310 in Oral Lichen Planus, Enrolls First PatientsJuly 29, 2024 | finanznachrichten.deLipella stock soars 200% on Phase 2 study initiationJuly 29, 2024 | msn.comWhy Is Lipella Pharmaceuticals (LIPO) Stock Up 149% Today?July 29, 2024 | investorplace.comLipella Pharmaceuticals Initiates Phase 2a Trial for LP-310 in Oral Lichen Planus, Enrolls First PatientsJuly 29, 2024 | globenewswire.comLipella Pharmaceuticals Announces Completion of Site Initiation Visit for Phase 2a Trial of LP-310 in Oral Lichen PlanusMay 31, 2024 | globenewswire.comLIPO Stock Earnings: Lipella Pharmaceuticals Reported Results for Q1 2024May 29, 2024 | investorplace.com Get Lipella Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for LIPO and its competitors with MarketBeat's FREE daily newsletter. Email Address LIPO Media Mentions By Week LIPO Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. LIPO News Sentiment▼1.000.57▲Average Medical News Sentiment LIPO News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. LIPO Articles This Week▼11▲LIPO Articles Average Week Get Lipella Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for LIPO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies TPST News Today CGTX News Today PASG News Today CYTH News Today LEXX News Today DRRX News Today KALA News Today LGVN News Today CALC News Today GRCE News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:LIPO) was last updated on 4/20/2025 by MarketBeat.com Staff From Our PartnersThe real reason gold is soaring (and likely to continue)Trump’s Policies Are Fueling a Gold Boom—Here’s Your Chance to Profit Donald Trump’s bold policies are driv...Golden Portfolio | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredThe first casualty of the 2025 trade warThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredMy prediction is coming trueWe've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by usi...InvestorPlace | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | SponsoredRead before the next tariff announcementLarry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lipella Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lipella Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
